Thomas Gad Sells 10,810 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB opened at $4.91 on Thursday. The company has a 50-day simple moving average of $6.16 and a 200 day simple moving average of $10.32. The company has a market capitalization of $222.02 million, a P/E ratio of -9.09 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 52-week low of $4.25 and a 52-week high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the business earned ($0.02) earnings per share. As a group, equities analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently bought and sold shares of YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Y-mAbs Therapeutics during the third quarter worth approximately $44,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $46,000. ProShare Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $99,000. Intech Investment Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $133,000. Finally, Wells Fargo & Company MN raised its position in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after buying an additional 6,131 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

YMAB has been the subject of several analyst reports. Truist Financial decreased their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Bank of America decreased their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.